Evidence map›Paper›PMID 36816758›Full record

ArticleMolecular therapy. Methods & clinical development2023

Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential.

Rosa A van Amerongen, Laura T Morton, Umesh G Chaudhari, Dennis F G Remst, Renate S Hagedoorn, Cathelijne W van den Berg, Christian Freund, J H Frederik Falkenburg, Mirjam H M Heemskerk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Leveraging T cells for cancer immunotherapy.Immunity & inflammation · 2025
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rosa A van AmerongenDepartment of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
Laura T MortonDepartment of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
Umesh G ChaudhariLUMC hiPSC Hotel, Department of Anatomy and Embryology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
Dennis F G RemstDepartment of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
Renate S HagedoornDepartment of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
Cathelijne W van den BergDepartment of Internal Medicine-Nephrology and Einthoven Laboratory of Vascular and Regenerative Medicine, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
Christian FreundLUMC hiPSC Hotel, Department of Anatomy and Embryology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
J H Frederik FalkenburgDepartment of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
Mirjam H M HeemskerkDepartment of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The balance between safety and efficacy of T cell therapies remains challenging and T cell mediated toxicities have occurred. The stringent selection of tumor-specific targets and careful selection of tumor-specific T cells using T cell toxicity screenings are essential.

Indexed as

adoptive T cell therapyhuman iPSCspreclinical screeningTCR gene transfertoxicity

Identifiers

PMID36816758
PMCPMC9931760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.